Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 11/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.52 |
| ▸ | TNF | P01375 | 4/20 | 0.44 |
| ▸ | IL1B | P01584 | 3/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21087880 | 0.88 | CRBN (0.46) | CRBNIKZF3DDB1TNF | |
| SCHEMBL19618073 | 0.87 | CRBN (0.66) | CRBNIKZF3DDB1TNFIL1B | |
| SCHEMBL19709449 | 0.84 | CRBN (0.52) | CRBNIKZF3DDB1TNFIL1B | |
| SCHEMBL22606726 | 0.83 | CRBN (0.47) | CRBNIKZF3DDB1TNFIL1B | |
| SCHEMBL20759891 | 0.83 | CRBN (0.44) | CRBNIKZF3DDB1TNFIL1B | |
| SCHEMBL18976195 | 0.83 | CRBN (0.53) | CRBNIKZF3DDB1TNFIL1B | |
| SCHEMBL22243461 | 0.83 | CRBN (0.51) | CRBNIKZF3DDB1TNFIL1B | |
| SCHEMBL19308879 | 0.80 | CRBN (0.54) | CRBNIKZF3DDB1 | |
| SCHEMBL23945771 | 0.79 | CRBN (0.46) | CRBNIKZF3DDB1TNFIL1B | |
| SCHEMBL29922394 | 0.79 | CRBN (0.77) | CRBNIKZF3DDB1TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | CRBN 1/4885IKZF3 855/4885DDB1 110/4885 |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885IKZF3 1040/4885DDB1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.